Corrigendum to “Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes” [Bioorg. Med. Chem. Lett. 22 (2012) 6218–6223]

MLA

Du, Xiaohui, et al. “Corrigendum to ‘Phenylalanine Derivatives as GPR142 Agonists for the Treatment of Type II Diabetes’ [Bioorg. Med. Chem. Lett. 22 (2012) 6218–6223].” Bioorganic & Medicinal Chemistry Letters, vol. 22, no. 24, Dec. 2012, p. 7750. EBSCOhost, https://doi.org/10.1016/j.bmcl.2012.10.021.

APA

Du, X., Kim, Y.-J., Lai, S., Chen, X., Lizarzaburu, M., Turcotte, S., Fu, Z., Liu, Q., Zhang, Y., Motani, A., Oda, K., Okuyama, R., Nara, F., Murakoshi, M., Fu, A., Reagan, J. D., Fan, P., Xiong, Y., Shen, W., & Li, L. (2012). Corrigendum to “Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes” [Bioorg. Med. Chem. Lett. 22 (2012) 6218–6223]. Bioorganic & Medicinal Chemistry Letters, 22(24), 7750. https://doi.org/10.1016/j.bmcl.2012.10.021

Chicago

Du, Xiaohui, Yong-Jae Kim, SuJen Lai, Xi Chen, Mike Lizarzaburu, Simon Turcotte, Zice Fu, et al. 2012. “Corrigendum to ‘Phenylalanine Derivatives as GPR142 Agonists for the Treatment of Type II Diabetes’ [Bioorg. Med. Chem. Lett. 22 (2012) 6218–6223].” Bioorganic & Medicinal Chemistry Letters 22 (24): 7750. doi:10.1016/j.bmcl.2012.10.021.